Published in Gene Therapy Weekly, July 22nd, 2004
"We have recently developed the so-called recombinant immunoporter as a non-viral vector based on a single-chain antibody (scFv) derived from a monoclonal antibody B4G7 against epidermal growth factor (EGF) receptor. This immunoporter (mBBD20) was composed of single-chain antibody and negatively charged oligopeptide tail [5 units of Asn4Ser (D20)], and was expressed in yeast as a secreted protein. The purified mBBD20 was converted to an immunogene by mixing it with DNA and a cationic polymer, polyethyleneimine (PEI)," researchers in Japan report.
"The resulting complex, namely recombinant immunogene,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.